Humulin r u-100, Insuman(insulin human)
Afrezza, Humulin, Insuman, Myxredlin, Novolin (insulin human) is a protein pharmaceutical. Insulin human was first approved as Humulin r u-100 on 1982-10-28. It has been approved in Europe to treat diabetes mellitus.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Afrezza, Humulin u, Myxredlin, Novolin (discontinued: Humulin u)
CombinationsHumulin, Novolin
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Insulin human
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Humulin R U-500 | insulin human | Eli Lilly | N-18780 RX | 1994-03-31 | 2 products |
| Humulin R U-100 | insulin human | Eli Lilly | N-18780 OTC | 1982-10-28 | 2 products |
| Afrezza | insulin human | Mannkind Corporation | N-22472 RX | 2014-06-27 | 3 products |
| Novolin R | insulin human | Novo Nordisk | N-19938 OTC | 1991-06-25 | 2 products |
Show 1 discontinued
Insulin human
+
Insulin isophane human
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Humulin 70/30 | insulin isophane human and insulin human | Eli Lilly | N-19717 OTC | 1989-04-25 | 3 products |
| Novolin 70/30 | insulin isophane human and insulin human | Novo Nordisk | N-19991 OTC | 1991-06-25 | 2 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| .insulin aspart protamine and insulin aspart | Biologic Licensing Application | 2024-02-22 |
| .insulin aspart protamine and insulin aspart insulin aspart protamine and insulin aspart | Biologic Licensing Application | 2019-11-15 |
| admelog | Biologic Licensing Application | 2023-09-19 |
| afrezza | Biologic Licensing Application | 2023-02-27 |
| apidra | 2008-11-06 | |
| apidra apidra solostar | Biologic Licensing Application | 2023-07-25 |
| basaglar | New Drug Application | 2019-01-28 |
| basaglar basaglar | Biologic Licensing Application | 2023-11-29 |
| esika extreme moisturizing spf 16 | OTC monograph final | 2013-12-20 |
| exubera | 2008-04-08 |
Show 53 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
7465 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 412 | 383 | 595 | 482 | 1586 | 3353 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 160 | 199 | 418 | 424 | 952 | 2102 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 252 | 240 | 208 | 148 | 897 | 1683 |
| Insulin resistance | D007333 | HP_0000855 | — | 96 | 151 | 73 | 119 | 894 | 1293 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 46 | 69 | 34 | 30 | 501 | 660 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | 16 | 54 | 20 | 27 | 218 | 321 |
| Syndrome | D013577 | — | — | 20 | 55 | 22 | 25 | 170 | 278 |
| Healthy volunteers/patients | — | — | — | 129 | 8 | 5 | 10 | 91 | 241 |
| Hyperglycemia | D006943 | HP_0003074 | R73.9 | 16 | 23 | 20 | 49 | 136 | 238 |
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | 27 | 27 | 12 | 17 | 161 | 237 |
Show 215 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 9 | 11 | 1 | — | 17 | 34 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 3 | 17 | 1 | — | 12 | 30 |
| Diabetes complications | D048909 | — | — | — | 4 | 5 | — | 14 | 19 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | 2 | 3 | — | 14 | 19 |
| Prostatic neoplasms | D011471 | — | C61 | 2 | 8 | 2 | — | 7 | 18 |
| Infections | D007239 | EFO_0000544 | — | — | 2 | 1 | — | 15 | 18 |
| Carcinoma | D002277 | — | C80.0 | 3 | 8 | 2 | — | 3 | 14 |
| Sepsis | D018805 | HP_0100806 | A41.9 | 2 | 3 | 2 | — | 8 | 14 |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | 1 | 5 | — | 4 | 11 |
| Septic shock | D012772 | — | A48.3 | 1 | 2 | 3 | — | 6 | 11 |
Show 104 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 9 | 4 | — | — | 15 | 27 |
| Exercise | D015444 | EFO_0000483 | — | — | 1 | — | — | 22 | 23 |
| Hyperandrogenism | D017588 | — | — | 1 | 5 | — | — | 7 | 12 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | 1 | 3 | — | — | 9 | 12 |
| Dementia | D003704 | EFO_0003862 | F03 | 2 | 6 | — | — | 4 | 11 |
| Autoimmune diseases | D001327 | HP_0002960 | M30-M36 | — | 2 | — | — | 8 | 10 |
| Metabolism | D008660 | GO_0008152 | — | — | 2 | — | — | 7 | 9 |
| Unconsciousness | D014474 | HP_0007185 | R40.20 | 2 | 3 | — | — | 6 | 9 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 6 | — | — | 3 | 9 |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | — | — | 7 | 8 |
Show 150 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sedentary behavior | D057185 | — | — | 1 | — | — | — | 22 | 23 |
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | 2 | — | — | — | 16 | 18 |
| Gastric bypass | D015390 | EFO_0005244 | — | 3 | — | — | — | 4 | 7 |
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | 1 | — | — | — | 5 | 6 |
| Carpal tunnel syndrome | D002349 | EFO_0004143 | G56.0 | 1 | — | — | — | 4 | 5 |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | 3 | — | — | — | 2 | 5 |
| Hepatitis b | D006509 | — | — | 1 | — | — | — | 3 | 4 |
| Death | D003643 | PATO_0001422 | — | 1 | — | — | — | 3 | 4 |
| Thrombosis | D013927 | — | — | 1 | — | — | — | 3 | 4 |
| Primary dysautonomias | D054969 | — | — | 3 | — | — | — | 1 | 4 |
Show 48 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Communicable diseases | D003141 | — | — | — | — | — | — | 11 | 11 |
| Blood glucose self-monitoring | D015190 | — | — | — | — | — | — | 11 | 11 |
| Pregnancy rate | D018873 | — | — | — | — | — | — | 10 | 10 |
| Healthy diet | D000072001 | — | — | — | — | — | — | 9 | 9 |
| Surgical wound infection | D013530 | — | — | — | — | — | — | 9 | 9 |
| Body composition | D001823 | — | — | — | — | — | — | 9 | 9 |
| Psoriasis | D011565 | EFO_0000676 | L40 | — | — | — | — | 8 | 8 |
| Fasting | D005215 | EFO_0002756 | — | — | — | — | — | 8 | 8 |
| Satiety response | D012528 | — | — | — | — | — | — | 8 | 8 |
| Nutritional and metabolic diseases | D009750 | — | — | — | — | — | — | 8 | 8 |
Show 433 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Insulin human |
| INN | insulin icodec |
| Description | Recombinant human insulin |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
Black-box warning for: Afrezza, Xultophy 100/3.6
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
227,663 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use